tiprankstipranks
Advertisement
Advertisement

HK:6990 Stock Latest News

Kelun-Biotech’s sac-TMT Combo Hits Phase 3 Milestone in First-Line Lung Cancer
Company AnnouncementsKelun-Biotech’s sac-TMT Combo Hits Phase 3 Milestone in First-Line Lung Cancer
4d ago
6990
Kelun-Biotech Raises HK$2.7 Billion in New H Share Placing to Fund R&D Expansion
PremiumCompany Announcements
Kelun-Biotech Raises HK$2.7 Billion in New H Share Placing to Fund R&D Expansion
8d ago
6990
Kelun-Biotech Raises HK$2.7 Billion via Hong Kong Share Placement
PremiumCompany Announcements
Kelun-Biotech Raises HK$2.7 Billion via Hong Kong Share Placement
11d ago
6990
Kelun-Biotech Consolidates Company Secretary Role After Chung Resigns
PremiumCompany Announcements
Kelun-Biotech Consolidates Company Secretary Role After Chung Resigns
11d ago
6990
Kelun-Biotech Boosts Structured Deposits with CZB and BOC
PremiumCompany Announcements
Kelun-Biotech Boosts Structured Deposits with CZB and BOC
18d ago
6990
Kelun-Biotech Shareholders Back All AGM Resolutions, Grant Board Wider Capital Mandates
PremiumCompany AnnouncementsKelun-Biotech Shareholders Back All AGM Resolutions, Grant Board Wider Capital Mandates
19d ago
6990
Kelun-Biotech Receives Over RMB700 Million from MediLink Settlement
Premium
Company Announcements
Kelun-Biotech Receives Over RMB700 Million from MediLink Settlement
1M ago
6990
Kelun-Biotech Sets 2026 AGM to Decide Profit Distribution and Capital Mandates
Premium
Company Announcements
Kelun-Biotech Sets 2026 AGM to Decide Profit Distribution and Capital Mandates
1M ago
6990
Kelun-Biotech Boosts CZB Structured Deposits to RMB590 Million
PremiumCompany Announcements
Kelun-Biotech Boosts CZB Structured Deposits to RMB590 Million
2M ago
6990
Kelun-Biotech Grants Performance-Linked RSUs Under 2025 Incentive Scheme
PremiumCompany Announcements
Kelun-Biotech Grants Performance-Linked RSUs Under 2025 Incentive Scheme
2M ago
6990
Kelun-Biotech’s Lung Cancer ADC Regimen Shows Strong Phase III Results at ASCO 2026
PremiumCompany Announcements
Kelun-Biotech’s Lung Cancer ADC Regimen Shows Strong Phase III Results at ASCO 2026
2M ago
6990
Kelun-Biotech Wins China IND Approval for Bispecific Cancer Antibody SKB118
PremiumCompany Announcements
Kelun-Biotech Wins China IND Approval for Bispecific Cancer Antibody SKB118
2M ago
6990
Kelun-Biotech’s sac-TMT Wins Priority Review for New Lung Cancer Use in China
PremiumCompany AnnouncementsKelun-Biotech’s sac-TMT Wins Priority Review for New Lung Cancer Use in China
2M ago
6990
Sichuan Kelun-Biotech Completes H Share Full Circulation Conversion
Premium
Company Announcements
Sichuan Kelun-Biotech Completes H Share Full Circulation Conversion
3M ago
6990
Kelun-Biotech Commits RMB690 Million to Structured Deposits in Treasury Move
Premium
Company Announcements
Kelun-Biotech Commits RMB690 Million to Structured Deposits in Treasury Move
3M ago
6990
Kelun-Biotech Drops Biotech Marker After Meeting Main Board Listing Thresholds
PremiumCompany Announcements
Kelun-Biotech Drops Biotech Marker After Meeting Main Board Listing Thresholds
3M ago
6990
Sichuan Kelun-Biotech Wins Approval for Full Circulation of Additional H Shares
PremiumCompany Announcements
Sichuan Kelun-Biotech Wins Approval for Full Circulation of Additional H Shares
3M ago
6990
Kelun-Biotech Wins CSRC Nod for H Share Full Circulation
PremiumCompany Announcements
Kelun-Biotech Wins CSRC Nod for H Share Full Circulation
4M ago
6990
Kelun-Biotech: Transitioning to Commercial Growth with sac-TMT as a Key Value Driver Supporting a Sustained Buy Rating
PremiumRatings
Kelun-Biotech: Transitioning to Commercial Growth with sac-TMT as a Key Value Driver Supporting a Sustained Buy Rating
4M ago
Kelun-Biotech Wins NMPA Green Light to Begin Trials of Novel Bispecific ADC SKB103
PremiumCompany AnnouncementsKelun-Biotech Wins NMPA Green Light to Begin Trials of Novel Bispecific ADC SKB103
4M ago
6990
Kelun-Biotech Widens Losses as It Accelerates ADC Push and Wins New China Approvals
Premium
Company Announcements
Kelun-Biotech Widens Losses as It Accelerates ADC Push and Wins New China Approvals
4M ago
6990
Kelun-Biotech’s Sacituzumab Tirumotecan Strengthens Lead in EGFR-Mutant Lung Cancer With Final Survival Data
Premium
Company Announcements
Kelun-Biotech’s Sacituzumab Tirumotecan Strengthens Lead in EGFR-Mutant Lung Cancer With Final Survival Data
4M ago
6990

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >